Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.72 |
| ▸ | CTSL | P07711 | 1/20 | 0.72 |
| ▸ | CTSB | P07858 | 1/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PTPRB | P23467 | 2/20 | 0.51 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988279 | 1.00 | CTSK (0.72) | CTSKCTSLCTSBHDAC6NPC1 | |
| SCHEMBL6683037 | 0.93 | CTSK (0.76) | CTSKCTSLCTSBHDAC6PTPRB | |
| SCHEMBL5934960 | 0.93 | CTSK (0.76) | CTSKCTSLCTSBHDAC6PTPRB | |
| SCHEMBL5935121 | 0.92 | CTSK (0.75) | CTSKCTSLCTSBHDAC6PTPRB | |
| SCHEMBL6987536 | 0.91 | CTSK (0.75) | CTSKCTSLCTSBHDAC6AAK1 | |
| SCHEMBL6981246 | 0.91 | CTSK (0.75) | CTSKCTSLCTSBHDAC6AAK1 | |
| SCHEMBL7165396 | 0.88 | CTSK (0.78) | CTSKCTSLCTSBHDAC6AAK1 | |
| SCHEMBL32667923 | 0.87 | ABCB1 (0.63) | CTSKCTSLCTSBHDAC6NPC1 | |
| SCHEMBL7175292 | 0.86 | CTSK (0.81) | CTSKCTSLCTSBHDAC6AAK1 | |
| SCHEMBL5934624 | 0.85 | CTSK (0.66) | CTSKCTSLCTSBHDAC6PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975612-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2001-06-13 | — | — | EP | claimed |
| EP-0975612-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-02 | — | — | EP | claimed |
| WO-1998046582-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-22 | — | — | WO | claimed |
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | disclosed |
| US-20020049316-A1 | Protease inhibitors | HALBERT STACIE MARIE (US) | 2002-04-25 | — | — | US | disclosed |
| US-6331542-B1 | TREATING DISEASES CHARACTERIZED BY BONE LOSS OR EXCESSIVE CARTILAGE OR MATRIX DEGRADATION | SMITHKLINE BEECHAM CORPORATION | 2001-12-18 | — | — | US | disclosed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999053039-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0804180-A1 | METHOD OF INHIBITING CATHEPSIN K | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997016177-A9 | METHOD OF INHIBITING CATHEPSIN K | — | 1997-07-24 | — | — | WO | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997016177-A1 | METHOD OF INHIBITING CATHEPSIN K | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049316-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSK 1/4885CTSL 10/4885CTSB 4/4885 |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | CTSK 64/4885CTSL 22/4885CTSB 35/4885 |
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSK 1/4885CTSL 14/4885CTSB 4/4885 |
| US-20020077455-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CTSK 1/4885CTSL 14/4885CTSB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.